Abstract 2568: Characterization of metabolic changes induced by anti-cancer drugs in MCF7 and MDA-MB-231 cell lines

2020 ◽  
Author(s):  
David L. Hoffman ◽  
Michael Pisano
Keyword(s):  
Cell Lines ◽  
Metabolic Changes ◽  
Cancer Drugs ◽  
Anti Cancer

Future Oncotargets: Targeting Overexpressed Conserved Protein Targets in Androgen Independent Prostate Cancer Cell Lines

2020 ◽  
Vol 20 (8) ◽  
pp. 1017-1027
Author(s):  
Abdul M. Baig ◽  
Zohaib Rana ◽  
Mohammad M. Mannan ◽  
Areeba Khaleeq ◽  
Fizza Nazim ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Cell Lines ◽  
Drug Efflux ◽  
Adapter Proteins ◽  
Cancer Drugs ◽  
Protein Targets ◽  
Anti Cancer ◽  
Drug Efflux Pumps ◽  
Cancer Agent ◽  
Androgen Independent

Background: Targeting evolutionarily conserved proteins in malignant cells and the adapter proteins involved in signalling that generates from such proteins may play a cardinal role in the selection of anti-cancer drugs. Drugs targeting these proteins could be of importance in developing anti-cancer drugs. Objectives: We inferred that drugs like loperamide and promethazine that act as antagonists of proteins conserved in cancer cells like voltage-gated Calcium channels (Cav), Calmodulin (CaM) and drug efflux (ABCB1) pump may have the potential to be re-purposed as an anti-cancer agent in Prostate Cancer (PCa). Methods: Growth and cytotoxic assays were performed by selecting loperamide and promethazine to target Cav, CaM and drug efflux (ABCB1) pumps to elucidate their effects on androgen-independent PC3 and DU145 PCa cell lines. Results: We show that loperamide and promethazine in doses of 80-100μg/ml exert oncocidal effects when tested in DU145 and PC3 cell lines. Diphenhydramine, which shares its targets with promethazine, except the CaM, failed to exhibit oncocidal effects. Conclusion: Anti-cancer effects can be of significance if structural analogues of loperamide and promethazine that specifically target Cav, CaM and ABCB1 drug efflux pumps can be synthesized, or these two drugs could be re-purposed after human trials in PCa.

Preparation and characterization of alginate gel core-lipid nanocapsules for co-delivery of hydrophilic and hydrophobic anti-cancer drugs

2014 ◽  
Vol 44 (7) ◽  
pp. 485-491 ◽  
Author(s):  
Bijay Kumar Poudel ◽  
Roshan Pradhan ◽  
Biki Gupta ◽  
Ju Yeon Choi ◽  
Chul Soon Yong ◽  
...  
Keyword(s):  
Cancer Drugs ◽  
Lipid Nanocapsules ◽  
Alginate Gel ◽  
Core Lipid ◽  
Anti Cancer

IL 1β attenuates the sensitivity of pancreatic carcinoma cell lines to anti-cancer drugs

2001 ◽  
Vol 120 (5) ◽  
pp. A661
Author(s):  
Alexande Arit ◽  
Jens Vomdamm ◽  
Hongang Yu ◽  
Wolfgang E. Schmidt ◽  
Ulrich R. Foelsch ◽  
...  
Keyword(s):  
Pancreatic Carcinoma ◽  
Cell Lines ◽  
Carcinoma Cell ◽  
Cancer Drugs ◽  
Carcinoma Cell Lines ◽  
Anti Cancer

Screening of 129 FDA approved anti-cancer drugs in colorectal cancer cell lines resistant to oxaliplatin or irinotecan (SN38).

2017 ◽  
Vol 35 (4_suppl) ◽  
pp. 642-642 ◽  
Author(s):  
Jan Stenvang ◽  
Christine Hjorth Andreassen ◽  
Nils Brünner
Keyword(s):  
Colorectal Cancer ◽  
Drug Resistance ◽  
Cell Viability ◽  
Cell Line ◽  
Cell Lines ◽  
Resistant Cell ◽  
Cancer Drug ◽  
Cancer Drugs ◽  
Drug Candidates ◽  
Anti Cancer

642 Background: In metastatic colorectal cancer (mCRC) only 3 cytotoxic drugs (oxaliplatin, irinotecan and fluorouracil (5-FU)) are approved and the first and second line response rates are about 50% and 10-15%, respectively. Thus, new treatment options are needed. Novel anti-cancer drug candidates are primarily tested in an environment of drug resistance and the majority of novel drug candidates fail during clinical development. Therefore, “repurposing” of drugs has emerged as a promising strategy to apply established drugs in novel indications. The aim of this project was to screen established anti-cancer drugs to identify candidates for testing in mCRC patients relapsing on standard therapy. Methods: We applied 3 parental (drug sensitive) CRC cell lines (HCT116, HT29 and LoVo) and for each cell line also an oxaliplatin and irinotecan (SN38) resistant cell line. We obtained 129 FDA approved anti-cancer drugs from the Developmental Therapeutics Program (DTP) at the National Cancer Institute (NCI) ( https://dtp.cancer.gov/ ). The parental HT29 cell line and the drug resistant sublines HT29-SN38 and HT29-OXPT were exposed to 3 concentrations of each of the anti-cancer drugs. The effect on cell viability was analyzed by MTT assays. Nine of the drugs were analyzed for effect in the LoVo and HCT116 and the SN38- and oxaliplatin-resistant derived cell lines. Results: None of the drugs caused evident differential response between the resistant and sensitive cells or between the SN38 and oxaliplatin resistant cells. The screening confirmed the resistance as the cells displayed resistance to drugs in the same class as the one they were made resistant to. Of the drugs, 45 decreased cell viability in the HT29 parental and oxaliplatin- or SN-38 resistant cell lines. Nine drugs were tested in all nine CRC cell lines and eight decrease cell viability in the nine cell lines. These included drugs in different classes such as epigenetic drugs, antibiotics, mitotic inhibitors and targeted therapies. Conclusions: This study revealed several possible new “repurposing” drugs for CRC therapy, by showing that 45 FDA-approved anti-cancer drugs decrease cell viability in CRC cell lines with acquired drug resistance.

scholarly journals Anti-Cancer Activity of Derivatives of 1,3,4-Oxadiazole

Molecules ◽  
2018 ◽  
Vol 23 (12) ◽  
pp. 3361 ◽  
Author(s):  
Teresa Glomb ◽  
Karolina Szymankiewicz ◽  
Piotr Świątek
Keyword(s):  
Biological Activity ◽  
Growth Factors ◽  
Cell Lines ◽  
Cancer Drugs ◽  
Inhibition Of Growth ◽  
Anti Cancer ◽  
The Future ◽  
Derivatives Of ◽  
Cancer Activity

Compounds containing 1,3,4-oxadiazole ring in their structure are characterised by multidirectional biological activity. Their anti-proliferative effects associated with various mechanisms, such as inhibition of growth factors, enzymes, kinases and others, deserve attention. The activity of these compounds was tested on cell lines of various cancers. In most publications, the most active derivatives of 1,3,4-oxadiazole exceeded the effect of reference drugs, so they may become the main new anti-cancer drugs in the future.

Synthesis and characterization of CD133 targeted aptamer–drug conjugates for precision therapy of anaplastic thyroid cancer

2021 ◽  
Author(s):  
Ming Hua Ge ◽  
Xu Hang Zhu ◽  
Yi Ming Shao ◽  
Chao Wang ◽  
Ping Huang ◽  
...  
Keyword(s):  
Thyroid Cancer ◽  
Anaplastic Thyroid Cancer ◽  
Synthesis And Characterization ◽  
Cancer Tissue ◽  
Cancer Drugs ◽  
Drug Conjugates ◽  
Anti Cancer ◽  
Precision Therapy

CD133 targeted aptamer–drug conjugates could precisely deliver anti-cancer drugs into CD133 positive anaplastic thyroid cancer tissue.

Sign in / Sign up

Export Citation Format

Share Document